(PharmaNewsWire.Com, December 06, 2018 ) Dual chamber prefilled syringes are being widely utilized for storing biological substances or active pharmaceutical components that cannot be stable for extended duration. These syringes enable avoiding drug loss by maintaining sterility of drugs prior to injection. Advancement in technology has resulted into improved arrangement of liquid components in syringes and injectors, attracting more patients toward opting for these safe and efficient syringes.
Lyophilized drugs have witnessed a robust penetration across the globe in the recent past. These drugs account for a major share of the all reconstitution-requiring injectable/infusible. As a large number of injectable/infusible drugs have been developed for self-administration, special challenges are incurred for the drug developers. However, dual chamber prefilled syringes, which are particularly designed for simplifying reconstitution devoid of patient handling of diluent or drug, have become the mainstay option for delivering these drugs, meanwhile curtailing challenges faced by developers. With lyophilized drugs witnessing proliferated penetration, demand for dual chamber prefilled syringes will gain a significant upsurge in the foreseeable future.
A CAGR of 8.7% has been projected for the Global Dual Chamber Prefilled Syringes Market during the forecast period, 2017 to 2026, according to a new study of Fact.MR. Roughly US$ 3,300 Mn worth of dual chamber prefilled syringes are likely to be sold across the globe by 2026-end.
North America will continue to be the most remunerative market for dual chamber prefilled syringes. Dominance of North America in the market can be highly attributed to growing prevalence of chronic diseases in the region coupled with high penetration of biologics and biosimilars. Geographical expansion of North America-based market players, high demand for self-injection devices and growing geriatric population are some other factors driving growth of the market in North America.
Conventional prefilled syringes are expected to remain sought-after among products in the global Dual Chamber Prefilled Syringes Market. This can be attributed to factors such as relatively lower cost along with robust adoption of self-administered drugs. Safety prefilled syringes are expected to record a comparatively faster sales expansion through 2026, mainly driven by growing focus of manufacturers in introducing technologically advanced and safe & efficient drug delivering prefilled syringes for minimizing risk to patients.
Glass to Remain Preferred Product Material for Dual Chamber Prefilled Syringes
Glass will remain preferred product material for dual chamber prefilled syringes, mainly because of its non-reactive nature, and properties such as chemical and heat resistance. However sales of glass prefilled syringes will witness a comparatively slower expansion than plastic prefilled syringes through 2026.
Although hospital pharmacies are estimated to account for the largest market share during the forecast period, sales of dual chamber prefilled syringes in online pharmacies are poised to record the highest CAGR through 2026.
With trend toward surging adoption of self-injection syringes, and development of technologically advanced dual chamber prefilled syringes, leading players in the market are concentrating on expansion of their product portfolio and the market reach. In this highly competitive and rapidly evolving market, players are emphasizing on the essentiality of up-to-date information for monitoring their performance and making critical decisions regarding profitability & growth.
Some players in the market are also focusing on making improvements in design of dual chamber prefilled syringes for improving stability and safety of sensitive drugs. Fact.MR’s report has listed key players augmenting the market expansion, which include Bespak Europe Ltd, Catalent, Inc., Credence MedSystems, Inc., Otsuka America Pharmaceutical, Inc., Schott AG, West Pharmaceutical Services, Inc., Ypsomed Holding AG, Gerresheimer AG, Vetter Pharma-Fertigung GmbH & Co. KG, Nipro Corporation, Boehringer Ingelheim GmbH, Amgen Inc., and Pfizer Inc.
About FactMR FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: